Arnold FW, et al. - Researchers performed secondary analysis of the Community-Acquired Pneumonia Organization database of hospitalized patients with community-acquired pneumonia (CAP) in order to determine the clinical outcomes of CAP patients with bacteremia treated with and without a macrolide. In-hospital all-cause mortality, 30-day mortality, length of stay, and time to clinical stability between these groups were the outcomes. A total of 549 patients with CAP and bacteremia were studied, of whom 247 (45%) were treated with a macrolide and 302 (55%) were not. They found that the macrolide group showed significantly better in-hospital mortality, but not 30-day mortality. Overall, the use of macrolide in such a patient population was supported.